Pfizer’s Meningitis B Vaccine Beats Novartis To Market, But ACIP Remains Key To Uptake
Executive Summary
The first-mover advantage for Trumenba remains unclear as CDC’s Advisory Committee on Immunization Practices holds crucial sway on vaccine use and commercial success; ACIP will vote on use of meningitis B vaccines in high-risk groups and during outbreaks in February 2015, but more widespread use recommendations may not be issued until late next year.
You may also be interested in...
Same-Day BLA Filings Show Pfizer Has Gained Ground On Novartis In Meningitis B
Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.